Jaguar Health, Inc. (JAGX)
NASDAQ: JAGX · Real-Time Price · USD
2.310
-0.060 (-2.53%)
Jul 10, 2026, 4:00 PM EDT - Market closed
Jaguar Health Revenue
Jaguar Health had revenue of $20.27M in the quarter ending March 31, 2026, with 815.63% growth. This brings the company's revenue in the last twelve months to $29.57M, up 155.96% year-over-year. In the year 2025, Jaguar Health had annual revenue of $11.51M, down -1.52%.
Revenue (ttm)
$29.57M
Revenue Growth
+155.96%
P/S Ratio
0.05
Revenue / Employee
$629,128
Employees
47
Market Cap
1.39M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 11.51M | -178.00K | -1.52% |
| Dec 31, 2024 | 11.69M | 1.93M | 19.75% |
| Dec 31, 2023 | 9.76M | -2.20M | -18.36% |
| Dec 31, 2022 | 11.96M | 7.62M | 175.80% |
| Dec 31, 2021 | 4.34M | -5.05M | -53.81% |
| Dec 31, 2020 | 9.39M | 3.61M | 62.51% |
| Dec 31, 2019 | 5.78M | 1.36M | 30.77% |
| Dec 31, 2018 | 4.42M | 54.96K | 1.26% |
| Dec 31, 2017 | 4.36M | 4.22M | 2,981.61% |
| Dec 31, 2016 | 141.52K | -116.86K | -45.23% |
| Dec 31, 2015 | 258.38K | - | - |
| Dec 31, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Scinai Immunotherapeutics | 1.21M |
| SciSparc | 856.00K |
| VivoSim Labs | 142.00K |
| Biodexa Pharmaceuticals | 104.90K |
| Azitra | 7.50K |
JAGX News
- 12 days ago - Jaguar Health provides recap of presentations of crofelemer at ESPGHAN - TheFly
- 13 days ago - Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF) - Accesswire
- 17 days ago - Jaguar Health announces conversion of Series O convertible preferred stock - TheFly
- 18 days ago - Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend - Accesswire
- 18 days ago - Jaguar Health Transcript: Life Sciences Virtual Investor Forum - Transcripts
- 19 days ago - Jaguar Health completes submission of NADA to U.S. FDA for crofelemer - TheFly
- 20 days ago - Jaguar Health Completes Submission of New Animal Drug Application for Full FDA Approval of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs - Accesswire
- 20 days ago - Jaguar Health initiates process to explore, review strategic alternatives - TheFly